We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GoOn Research and Development Project Wins Theseus-Mittelstand
News

GoOn Research and Development Project Wins Theseus-Mittelstand

GoOn Research and Development Project Wins Theseus-Mittelstand
News

GoOn Research and Development Project Wins Theseus-Mittelstand

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GoOn Research and Development Project Wins Theseus-Mittelstand"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Transinsight has announced that the consortium formed with RESprotect, Antikorper-Online, and the Bioinformatics group of Prof. Dr. Michael Schroeder at TU Dresden, has won the Theseus-Mittelstand for R&D project GoOn. Over the next two years, the project -based on the results of Theseus One- will develop praxis-relevant semantic technologies for information handling in the biomedical domain.

The first goal of the project is to develop a specialized search engine to find antibody mentions in ordinary -not only scientific- texts. Antibodies play an important role in modern pharmaceutical research when, for example, labeling genes and proteins for optical particle tracking. Gene and protein names do not belong to a standardized nomenclature and developed rather organically in the years of their discovery.

Of the approximate 500,000 to 1,000,000 human proteins, each protein has an average of five synonyms and often hundreds of spelling variants. Furthermore, there are some proteins that share a common name and for which the context needs to be analyzed in order to classify them properly. Transinsight will work closely with antibody vendor Antikorper-Online on this area of the project to develop intelligent matching algorithms and new semantic advertisement technologies.

The second goal is the development of a semantic platform to elucidate gene interaction networks. Transinsight, RESprotect, and TU Dresden will work together to develop methods for the elucidation of BVDU, a highly promising drug against pancreatic cancer, currently in late-stage clinical trial. The end goal is to integrate all textual information with already known data to better understand the activity of the drug and optimize subsequent compounds.
Advertisement